The BSE Sensex snapped a four-day losing streak to edge higher on Friday, rebounding as Tata Steel surged after its March-quarter operating profit beat analyst estimates and as recently beaten-down blue-chips such as Larsen & Toubro recovered. Full Article
For months, markets have been dancing to central bankers' tune, but that may now be changing, writes James Saft. Full Article
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
GlaxoSmithKline has no plans to delist Indian arm - exec
MUMBAI (Reuters) - GlaxoSmithKline Plc (GSK.L) has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare Ltd (GLSM.NS), David Redfern, chief strategy officer at Britain's biggest drugmaker, said on Monday.
GSK said earlier it planned to buy up to an additional 31.8 percent stake in the Indian unit for 52.2 billion rupees.
The company has been expanding into both emerging markets and non-prescription consumer health - and in some cases a combination of the two.
The company, which plans to launch new variants of the flagship Horlicks brand in India, is looking to increase penetration of the product in the north and western regions of the country, Redfern said. (Reporting by Kaustubh Kulkarni; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this